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In an attempt to genetically modify cultured keratinocytes
with transforming growth factor-β1 (TGF-β1), which has
been proven to be one of the most important cytokines
involved in wound healing, two constructs were made.
One, designated pG3Z:K14-TGF-β1, is a plasmid in
which the expression of TGF-β1 is driven by the keratin
14 promoter. The other, designated pLin-TGF-β1, is a
retroviral vector in which the retroviral 59 long-terminal
repeat promoter drives expression. In both constructs,
the deletion of a small fragment of the noncoding region
of the TGF-β1 gene was made to differentiate the tran-
script from that for endogenously expressed TGF-β1.
Different types of cells were transfected with the
pG3Z:K14-TGF-β1 construct using the calcium phos-
phate method. The pLin-TGF-β1 construct was propag-
ated in a retroviral packaging cell line and conditioned
medium that contained high titers of the virus was used
to transduce keratinocytes or other types of cells grown
in standard culture. Northern analysis, used to evaluate
the expression of TGF-β1 mRNA in the pG3Z:K14-TGF-
β1 transfected keratinocyte Cl-177 cell line, showed a
smaller TGF-β1 transcript compared with that endogen-
ously expressed by dermal fibroblasts. The level of TGF-
Transforming growth factor β1 (TGF-β1) is a multifunc-tional cytokine that influences many important physio-logic processes, such as cellular proliferation anddifferentiation (Sporn et al, 1986). This cytokine issecreted as a latent high molecular weight complex
(L-TGF-β), consisting of a 25 kDa dimeric mature protein with 112
amino acids in each subunit and the dimeric N-terminal precursor
peptide known as the latency associated peptide (Tsuji et al, 1990).
TGF-β1 is a member of a large family of proteins consisting of five
TGF-β isoforms (TGF-β1–5), bone morphogenetic proteins, inhibins,
activins, and mullerian inhibiting substance. TGF-β isoforms share 70–
80% sequence identity and the sequences of the mature, proteolytically
processed forms of each member are highly conserved between species
(Roberts and Sporn, 1989). TGF-β1, 2, and 3 have been found in
mammals and their tissue specific differential expression may have
important biologic consequences (Ghahary et al, 1996).
Manuscript received November 30, 1997; revised January 26, 1998; accepted
for publication January 30, 1998.
Reprint requests to: Dr. Aziz Ghahary, 161 HMRC, 8440–112 Street,
University of Alberta, Edmonton, Canada, T6G 2B7.
Abbreviation: LTR, long-terminal repeat.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
800
β1 protein evaluated by enzyme-linked immunosorbent
assay was significantly higher in medium conditioned by
either the K14-TGF-β1 transfected or the pLin-TGF-β1
transduced keratinocytes, compared with that obtained
from control cells; however, the level of TGF-β1 protein
was unchanged in cultures of pG3Z:K14-TGF-β1 trans-
fected nonkeratinocyte cells such as fetal and adult
fibroblasts. Using the mink lung epithelial cell growth
inhibition assay, we found an increase in TGF-β1 activity
in conditioned medium from the pG3Z:K14-TGF-β1
transfected cells. To evaluate possible paracrine effects of
the keratinocyte derived TGF-β1, a coculture system was
established with pLin-TGF-β1 transduced keratinocytes
grown in the upper chamber and dermal fibroblasts in
the lower chamber. The results showed that TGF-β1
released from keratinocytes diffused to the lower chamber
where it stimulated collagen production by dermal
fibroblasts. In summary, we demonstrate here that prim-
ary cultured keratinocytes can be genetically modified to
express high levels of TGF-β1 and suggest that this offers
a potential approach for the therapy of dermal lesions such
as nonhealing wounds. Key words: co-culture/fibroblasts/gene
therapy/keratinocyte/K14/retroviral vector/TGF-β1. J Invest
Dermatol 110:800–805, 1998
It is well known that TGF-β1 is one of the most effective growth
factors stimulating the synthesis and deposition of various extracellular
matrix proteins important in differentiation, morphogenesis, and wound
healing (Goldstein et al, 1989; Roberts and Sporn, 1989; Hill et al,
1992). TGF-β1 stimulates fibroblasts to synthesize collagen, fibronectin,
and glycosaminoglycans (Ignotz and Massague, 1986; Sporn et al,
1987); it enhances neovascularization (Allen et al, 1993) and modulates
the production of several proteases and their inhibitors (Edwards et al,
1987; Overall et al, 1989). TGF-β1 is a very potent chemoattractant
for monocytes (Wakefield et al, 1987) and fibroblasts (Postlethwaite
et al, 1987). Subcutaneous injection into newborn mice stimulates
granulation tissue formation (Roberts et al, 1986) and it has also been
shown to accelerate healing of incisional wounds in rats (Mustoe
et al, 1987).
The process of cultivating keratinocytes in vitro to confluency for
grafting onto patients with severe thermal injuries has been well
established (Green et al, 1979). O’Connor et al were the first to use
autologous cultured keratinocytes for grafting on to a burn wound
(O’Connor et al, 1981). The use of cultured epithelial autografts has
not only been beneficial for patients with massive burns, but has also
been successfully used for the treatment of giant congenital nevi
(Gallico et al, 1989) and junctional epidermal bullosa (Carter et al,
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1987) and in post-burn scar revision (Kumagai et al, 1988). Although
cultured epithelial autografts have a recognized limitation for wound
healing in burn patients, the technique offers the advantage of minimal
donor site requirements and the potential for the molecular biologic
manipulation of target cells. Keratinocyte gene therapy therefore offers
enormous potential for novel therapeutic approaches not only following
thermal injury, but for other congenital and acquired disorders of the
skin (Fabre and Cullen, 1989). We describe here the construction and
evaluation of two vectors, pG3Z:K14-TGF-β1 and pLin-TGF-β1,
carrying the TGF-β1 gene. The K14 promoter-driven TGF-β1 is
specifically targeted to cultured keratinocytes whereas the retroviral
long-terminal repeat (LTR) promoter-driven TGF-β1 should be
expressed in any cell type, including cultured keratinocytes. It is the
aim of this study to provide evidence that keratinocytes that may be
used as wound coverage can be genetically modified to express high
levels of TGF-β1.
MATERIALS AND METHODS
Construction of the pG3Z:K14-TGF-b1 and pLin-TGF-b1 vectors
Two vectors were constructed to express human TGF-β1 in keratinocytes. To
specifically target the expression of this cytokine to keratinocytes, the pG3Z:K14
cassette, in which the keratin 14 promoter drives the expression of TGF-β1,
was used. The K14 cassette contains a keratin-14 promoter/enhancer in the
Ava 1 restriction site that is upstream of a K14 polyadenylation signal. In this
cassette, there is a BamH1 restriction site located between the K14 promoter
and polyadenylation sequences in which the cDNA of interest may be cloned;
however, we could not use this site because the TGF-β1 cDNA has a BamH1
restriction site within its coding region. To overcome this problem, the
overhanging ends created by Pst I and EcoR1 in the TGF-β1 cDNA and by
BamH I in the vector were filled with the Klenow fragment. The blunt-ended
Pst1-EcoR1 fragment of TGF-β1 cDNA, containing 76 nucleotides of the 59
untranslated region, an ATG start codon, a sequence coding for the 390 amino
acids of L-TGF-β1, and 176 nucleotides of the 39 untranslated region, was
then subcloned into the blunt-ended restriction site downstream of the K14
promoter in the pG3Z:K14 cassette (Fig 1A). This construct is designated
pG3Z:K14-TGF-β1. The K14 promoter has been successfully used to drive
the expression of IL-6 cDNA in keratin-14 expressing epithelial cells in the
skin of transgenic mice (Turksen et al, 1992).
A second construct, in which a moloney murine leukemia virus 59 LTR
promoter drives the expression of TGF-β1, was also made. The proviral
structure of the L-TGF-β1 retroviral vector, referred to as pLin-L-TGF-β1
(Fig 1B), carries the 59 and 39 viral LTR, a neomycin-resistance gene, and a
latent TGF-β1 construct that consists of 76 nucleotides of the 59 untranslated
region, an ATG start codon, a sequence coding for the 390 amino acids of L-
TGF-β1, and 68 nucleotides of the 39 untranslated region.
Gene transfection and transduction The pG3Z:K14:TGF-β1 construct
was used to transfect cultured Hela cells, the XB-2 keratinocyte cell line
(ATCC, CL-177), fetal and adult fibroblasts, and primary human keratinocytes.
To optimize conditions for transfection with calcium phosphate or liposomes,
the XB-2 keratinocyte cell line was used with 14C-labeled chloramphenicol in
a chloramphenicol acetyltransferase assay. The result showed greater chloram-
phenicol acetyltransferase activity with the calcium phosphate precipitation and
therefore this technique was used in all subsequent experiments (data not
shown). The success of this transfection was also evaluated by northern analysis
for TGF-β1 mRNA and by enzyme-linked immunosorbent assay (ELISA) and
the mink lung epithelial cell growth inhibition assay of conditioned medium
for protein.
The pLin-TGF-β1 retroviral vectors lack the gag, pol, and env genes required
for viral packaging and are therefore replication incompetent and cannot be
propagated in any cell with a normal genome. Therefore, calcium phosphate
precipitation was employed to introduce this construct into a PA317 packaging
cell line that possesses viral structural proteins for vector. Packaging cells were
enriched by growth in the presence of 0.5 mg G-418 for 6–10 d. A total of
53 packaging cell colonies resistant to the antibiotic were screened and eight
colonies with high TGF-β1 production titers (3–4 ng per ml) were selected
and subcultured. At confluency, conditioned medium was collected, assayed
for TGF-β1 protein, and used for transduction of primary keratinocytes.
Cell cultures The procedure of Rheinwald and Green (1975) was used for
cultivation of human foreskin keratinocytes using serum-free keratinocyte
medium (GIBCO, Grand Island, NY) supplemented with bovine pituitary
extract (25 µg per ml) and epidermal growth factor (0.5 ng per ml). Primary
cultured keratinocytes at passages 3–5 were used. Keratinocytes were then
grown alone or in the upper chamber of a coculture system with dermal
fibroblasts in the lower chamber. In this system TGF-β1 released from the
pLin-TGF-β1 transduced keratinocytes can diffuse through the 0.4 µm porous
membrane separating the two chambers. To establish the fibroblast cultures,
either fetal foreskin or normal skin punch biopsies obtained from patients
undergoing elective reconstructive surgery, were established in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum as
previously described (Ghahary et al, 1994). Strains of dermal fibroblasts at
passages 3–7 were used in this study. Other cells, such as Hela cells, XB-2
keratinocytes, and pA317 packaging cells, were obtained from the American
Type Culture Collection (12301-Parklawn Drive, Rockville, MD) and main-
tained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum.
Extraction of cellular RNA and northern analysis To demonstrate
whether the K14 promoter drives the expression of TGF-β1 mRNA, XB-2
keratinocytes were transfected with either pG3Z:K14-TGF-β1 or pG3Z:K14
construct alone and 72 h later the culture medium was removed and cell layers
were lysed in 6 ml of guanidinium thiocyanate as previously described (Ghahary
et al, 1994). Total RNA was extracted by the guanidinium isothiocyanate/CsCl
procedure of Chirgwin et al (1979), separated by electrophoresis, and blotted
onto nitrocellulose filters. Filters were then baked under vacuum for 2 h at
80°C and prehybridized in a solution containing 50% formamide, 0.3 M sodium
chloride, 20 mM Tris HCl (pH 8.0), 1 mM ethylenediamine tetraacetic acid,
1X Denhardt’s solution (1X 5 0.02% bovine serum albumin, Ficoll and
polyvinylpyrrolidone), 0.005% salmon sperm DNA, and 0.005% poly (A) for
2–4 h at 45°C. Hybridization was performed in the same solution at 45°C for
16–20 h using cDNA probes for either human TGF-β1 or β-actin. The probes
were labeled with 32P-α-dCTP (DuPont Canada, Streetsville, Mississauga,
Ontario, Canada) by nick-translation. Filters were initially washed at room
temperature with 2 3 sodium citrate/chloride buffer (1X 5 0.15 M sodium
chloride, 0.015 M sodium citrate) and 0.1% sodium dodecyl sulfate for 30 min,
then for 20 min at 65°C in 0.1 3 sodium citrate/chloride buffer and 0.1%
sodium dodecyl sulfate solution. Autoradiography was performed by exposing
Kodak X-Omat film to the nitrocellulose filters at –70°C in the presence of an
enhancing screen. The human TGF-β1 cDNA was a gift from Dr. G.I. Bell
(Howard Hughes Medical Institute, Department of Biochemistry and Molecular
Biology and Medicine, University of Chicago, IL). β-actin cDNA was obtained
from the American Type Culture Collection (Rockville, MD).
Enzyme-linked immunosorbent assay for TGF-b1 To determine the
amounts of TGF-β1 produced by pG3Z:K14-TGF-β1 transfected or pLin-
TGF-β1-transduced cells, a sandwich ELISA for TGF-β1 was used (Danielpour,
1993). Briefly, 96 well plates were coated with 100 µl per well of monoclonal
antibody to human TGF-β (Genzyme, Cambridge, MA) at a concentration of
1 µg per ml in phosphate-buffered saline (PBS). The plates were incubated for
2 h at room temperature followed by 16 h at 4°C. After washing twice with
PBS-Tween-20 (PBS-T), the plates were blocked with 1% bovine serum
albumin (crystallized, Sigma, St Louis, MO) for 60 min at room temperature
and washed three times with PBS-T. One milliliter of conditioned medium
from each culture sample was acidified with 24 µl of 5N HCl for 15 min at
room temperature and neutralized with 40 µl of 1 M HEPES/5 N NaOH (5/
2). One hundred microliters of the acidified/neutralized samples was added to
each well of the plates, which were then incubated at room temperature for
60 min. After washing, the plates were incubated with 100 µl per well of chicken
anti-human TGF-β (R&D Systems, Minneapolis, MN) at a concentration of
2.5 µg per ml for 60 min at room temperature with shaking. After washing
five times with PBS-T, the plates were incubated with alkaline phosphatase-
conjugated rabbit anti-chicken IgG (Sigma) at room temperature for 60 min
followed by five washings with PBS-T. After adding substrate (o-nitrophenyl
phosphate, 1 mg per ml, Sigma), the plates were incubated at room temperature
for 60 min and the optical density was read using a THERMOmax (Molecular
Devices, Menlo Park, CA) microplate reader at a wave length of 405 nm. Serial
dilutions (0, 125, 250, 625, 1250, to 2500 pg per ml) of recombinant human
TGF-β1 (Genzyme) were used to prepare a standard curve.
Epithelial cell growth-inhibition assay The mink-lung epithelial cell
(CCL-64, American Culture Tissue Type) growth-inhibition assay and prepara-
tion of conditioned media were used as described (Danielpour et al, 1989;
Ghahary et al, 1998). Briefly, subconfluent cultures were trypsinized, washed
in assay medium (Dulbecco’s modified Eagle’s medium, 0.2% fetal bovine
serum, 10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, and 1%
penicillin/streptomycin antibiotic), seeded at 5 3 105 per 0.5 ml per well in
24 well plates, and incubated for 3 h at 37°C in an atmosphere of 5% CO2.
Various volumes (0, 1, 2.5, 5, 10, 20, and 40 µl) of low-serum conditioned
media obtained from the pG3Z:K14-TGF-β1 transfected and untransfected
cells or a standard amount of TGF-β1 (Genzyme) was then added. Twenty-
two hours later 0.25 mCi of 3H-labeled thymidine was added to each well for
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Figure 1. Scheme for the construction and
amplification of the pG3Z-K14:TGF-β1 and
pLin-TGF-β1 retroviral vectors. (A) The
Pst1-EcoR1 fragment of TGF-β1 cDNA
containing 76 nucleotides of the 59 untranslated
region, an ATG start codon, a cDNA coding
sequence for 390 amino acid of L-TGF-β1, and
176 nucleotides of the 39 untranslated region that
has been excised and subcloned into the BamH1
restriction site located downstream of the K14
promoter of the pG3Z:K14 cassette as described
in the Materials and Methods. The K14 cassette
contains a keratin-14 promoter/enhancer in the
Ava 1 restriction site that is upstream of a K14
polyadenylation signal at the 39 end. (B) The
structure of L-TGF-β1 retroviral vector referred
to as pLin-L-TGF-β1 carrying a 59 LTR and a
DNA sequence corresponding to the latent TGF-
β1 construct identical to that described in (A).
Latent TGF-β1 with 390 amino acids released
from either pG3Z-K14:TGF-β1 transfected or
pLin-TGF-β1 transduced cells is also shown. j,
Mature TGF-β1; u, latency associated protein.
2 h and incubation continued. Cells were then fixed, washed, and the
radioactivity was measured in the cell lysate collected from each well.
Hydroxyproline analysis by gas chromatography/mass spectrometry
To examine whether TGF-β1 released from pLin-TGF-β1 transduced ker-
atinocytes grown in the upper chamber of a coculture system can stimulate
production of collagen by dermal fibroblasts grown in the lower chamber, the
hydroxyproline content of the medium was measured as previously described
(Tredget et al, 1993). Briefly, the medium was dried in a rotary evaporator after
adding a known amount of hydroxypipecolic acid as internal standard. Samples
were hydrolyzed in 0.5 ml of 6N HCl at 116°C for 16 h. The N,O-
trifluoroacetyl N, methyl ester derivative of hydroxyproline was prepared after
drying the hydrolysate. Gas chromatography/mass spectrometry analysis was
performed on an HP 5890 GC linked to a HP 5970 MSD (mass selective
detector) monitoring the ions m/z-164 and 278. Each sample was run in
triplicate and the results expressed as pg hydroxyproline per ml of medium per
48 h obtained by reference to a standard curve of collagen analyzed under
identical conditions.
Statistical analysis The differences in hydroxyproline and TGF-β1 protein
production between either the pG3Z:K14-TGF-β1 transfected and untrans-
fected or the pLin-TGF-β1 transduced and untransduced cells were calculated
and compared. The statistical significance was evaluated using Student’s t test;
p values of , 0.05 were considered significant.
RESULTS
Keratin 14 promoter drives the expression of TGF-β1 mRNA
in keratinocytes To examine whether the pG3Z:K14-TGF-β1 was
constructed correctly and whether the K14 promoter drives the
expression of the TGF-β1 transcript in keratinocytes, XB-2 ker-
atinocytes (Cl-177 cell line) were transfected using the calcium phos-
phate precipitation method and the total RNA was extracted and
evaluated by northern analysis. In all experiments, the pG3Z:K14
vector with no TGF-β1 insert was used as a negative control. Total
RNA from two different strains of dermal fibroblasts was also extracted
and analyzed as a control for the endogenously expressing TGF-β1
transcript. As shown in Fig 2, the TGF-β1 transcript is highly
expressed in the pG3Z:K14-TGF-β1 transfected keratinocytes (Fig 2,
keratinocytes, lane 1) and this transcript is smaller than that expressed
by two strains of dermal fibroblasts (fibroblast lanes) examined. Re-
hybridization of the same blot with a probe specific for β-actin
revealed that the apparently high expression of TGF-β1 in transfected
keratinocytes and its smaller apparent size are not due to variations in
loading or in mobility of RNA during electrophoresis (Fig 2a, β-actin
band). These results show that the K14 promoter can drive the
expression of mRNA for TGF-β1. To examine whether this TGF-β1
is expressed at the protein level and released from transfected cells,
conditioned medium was evaluated by ELISA. The results (Fig 2b)
revealed a 2-fold increase in TGF-β1 in conditioned medium derived
from transfected cells relative to the control.
Figure 2. The keratin 14 promoter drives the expression of TGF-β1
mRNA and protein in pG3Z:K14:TGF-β1 transfected XB-2
keratinocytes. (a) Total RNA from either pG3Z:K14-TGF-β1 (1), pG3Z:K14
(–) transfected XB-2 keratinocytes or two strains of untransfected dermal
fibroblasts hybridized initially with human TGF-β1 cDNA and subsequently
with a cDNA specific for β-actin used as a control for RNA loading. (b) The
quantitative analysis of TGF-β1 in conditioned medium of transfected and
untransfected keratinocytes, measured by ELISA as described in the Materials
and Methods. Data are shown as means 6 SEM for three separate experiments
done in duplicate. The asterisk denotes a significant difference (p , 0.05) in
production of TGF-β1 between the pG3Z:K14:TGF-β1 and pG3Z:K14
transfected cells.
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Figure 3. The keratin 14 promoter specifically drives the expression of
TGF-β1 in keratinocytes but not in mesenchymal cells. Conditioned
medium from either pG3Z:K14:TGF-β1 transfected Hela cells, Cl-177
keratinocytes, adult fibroblasts, or fetal foreskin fibroblasts (j) and the
pG3Z:K14-transfected negative control cells (u) was collected and the TGF-
β1 was measured by ELISA (A). Data are expressed as means 6 SEM for two
separate experiments done in triplicate. (B) A dose response curve for the
biologic activity of TGF-β1 in the CL-177 cell conditioned medium, evaluated
by the mink lung epithelial cell growth inhibition assay using [3H]thymidine
incorporation as an index of DNA synthesis. Data represent the means 6 SEM
of three different experiments done in triplicate. The asterisk denotes a significant
difference (p , 0.05) in the inhibition of thymidine incorporation between the
pG3Z:K14:TGF-β1 and pG3Z:K14-transfected cells. s, condition medium
derived from pG3Z:K14:TGF-β1 transfected cells; d, condition medium
derived from pG3Z:K14 transfected cells.
Activity of the keratin 14 promoter is specific for
keratinocytes To address the question of how specific the K14
promoter is for keratinocytes, conditioned medium derived from
pG3Z:K14:TGF-β1 transfected Hela cells, adult fibroblasts, or fetal
foreskin fibroblasts was assayed by ELISA, using the pG3Z:K14
transfected cells as negative controls. The results shown in Fig 3(A)
revealed that the K14 promoter is highly active only in the CL-177
keratinocytes. No significant difference in TGF-β1 production was
found between pG3Z:K14:TGF-β1 transfected and untransfected for
any of the other cell strains examined. In general, the level of
endogenous TGF-β1 production was also markedly higher in the CL-
177 cells.
The biologic activity of TGF-β1 released from CL-177 cells was
evaluated in the mink lung epithelial cell growth inhibition assay using
[3H]thymidine incorporation as an index for inhibition of DNA
synthesis. As TGF-β1 is secreted by many different cell strains in an
Figure 4. The keratin 14 promoter drives the expression of TGF-β1 in
cultured keratinocytes. Primary cultured keratinocytes were established from
fetal foreskin tissues as described in the Materials and Methods. Cells were
transfected with either the pG3Z:K14:TGF-β1 or the pG3Z:K14 constructs
(control), conditioned medium was collected and TGF-β1 was measured by
ELISA. The data represent the means 6 SEM for three separate experiments
done in duplicate. The asterisk denotes a significant difference (p , 0.05) in
TGF-β1 protein between pG3Z:K14:TGF-β1 transfected and control
keratinocytes.
inactive (latent) form (Sporn et al, 1986), conditioned medium derived
from transfected and untransfected cells was acidified and then neutral-
ized prior to being added to the mink lung epithelial cells. This
experiment revealed that conditioned medium from pG3Z:K14:TGF-
β1 transfected CL-177 cells had a greater inhibitory effect on the
thymidine incorporation into the DNA of the mink lung epithelial
cells than that obtained from untransfected control cells (Fig 3B). This
finding indicates that the TGF-β1 released from transfected cells
can interact (after activation) with the receptors on the mink lung
epithelial cells.
The activity of the K14 promoter has also been examined in primary
cultured keratinocytes. Results of an ELISA assay revealed a more than
2-fold increase (77.8 6 12.4 vs 29.3 6 8.8 pg per 105 cells, p , 0.05)
in TGF-β1 production by pG3Z:K14:TGF-β1 transfected keratinocytes
relative to pG3Z:K14 transfected control cells (Fig 4). This further
confirmed that the K14 promoter drives the expression of TGF-β1
specifically in keratinocytes rather than mesenchymal cells.
A retroviral LTR promoter drives the expression of TGF-b1 in
primary cultured keratinocytes As another approach to genetically
modifying the expression of TGF-β1 in keratinocytes, a retroviral
vector bearing pLin-TGF-β1 containing an aminoglycoside 39 phos-
photransferase antibiotic resistant gene has been constructed. A total
of eight of 53 packaging cell colonies resistant to G-418 were screened,
selected on the basis of high TGF-β1 production (3–4 ng per ml),
and subcultured. Conditioned medium collected at confluency was
evaluated for TGF-β1 protein and used for transduction of primary
keratinocytes, cultured alone or with dermal fibroblasts. As shown in
Fig 5(A), the concentration of TGF-β1 detected by ELISA is higher
in conditioned medium from pLin-TGF-β1 transduced keratinocytes
relative to that from control cells. Co-culture of these keratinocytes
with dermal fibroblasts led to an increase in collagen production by
the latter (Fig 5B). These findings demonstrate that keratinocytes can
be readily modified with the pLin-TGF-β1 retroviral vector to produce
a high level of TGF-β1 that can stimulate collagen production by
dermal fibroblasts.
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Figure 5. TGF-β1 released from primary keratinocytes increases the
collagen production by dermal fibroblasts. The retroviral vector pLin-
TGF-β1 was constructed and propagated in a PA317 packaging cell line in the
presence of geneticin (G-418) as shown in Fig 1. Conditioned medium from
the pLin-TGF-β1 transduced and untransduced packaging cells was then
collected and used to transduce primary cultured keratinocytes. (A) Comparison
of the concentration of TGF-β1 evaluated by ELISA in conditioned medium
of pLin-TGF-β1 transduced and untransduced keratinocytes. These cells
(keratinocytes) were then grown in the upper chamber of a coculture system
in which dermal fibroblasts were grown in the lower chamber. (B) The effect
of diffusible keratinocyte derived TGF-β1 on hydroxyproline used as an index
for collagen production by dermal fibroblasts. Data represent means 6 SEM
for three separate experiments done in duplicate. The asterisk denotes a
significant difference (p , 0.05) in TGF-β1 protein and hydroxyproline either
between the pLin-TGF-β1 transduced and untransduced keratinocytes or
between fibroblasts cocultured with the pLin-TGF-β1 transduced and
untransduced keratinocytes, respectively.
DISCUSSION
The multifunctional characteristics of TGF-β1 make it a unique
cytokine for possible treatment of nonhealing wounds or to accelerate
the normal process of healing in severe thermal injury. This is because
it modulates the synthesis and deposition of various extracellular matrix
proteins such as fibronectin, collagenase, type I collagen, and type III
collagen by dermal fibroblasts (Goldstein et al, 1989; Roberts and
Sporn, 1989; Hill et al, 1992). This cytokine also enhances the
production of protease inhibitors such as tissue metalloproteinase
inhibitor-1 (Edwards et al, 1987; Overall et al, 1989), glycosaminogly-
cans (Ignotz and Massague, 1986; Sporn et al, 1987), and neovasculariz-
ation (Allen et al, 1993).
The efficacy of any growth factor, including TGF-β1 in the
stimulation of extracellular matrix in vivo, depends on the route by
which it is delivered to the wound. Its efficacy is likely to be markedly
depressed when administered topically or intravenously due to instability
of the mature TGF-β1. Additionally, this approach may not be cost
effective. Another approach might be to deliver the growth factor
through cultured keratinocytes used as wound coverage. This approach
is feasible because several studies have demonstrated that cultured
epithelial autografts can successfully be used for wound coverage in
patients with large thermal injuries, giant congenital nevi (Green et al,
1979; Gallico et al, 1989), and junctional epidermal bullosa (Carter
et al, 1987) and in post-burn scar revision (Kumagai et al, 1988). This
technique offers the advantage of minimal donor site requirements and
the potential for molecular biologic manipulation of the keratinocytes
during culture where they are readily accessible.
This study was conducted to examine the hypothesis that ker-
atinocytes can be genetically modified to express TGF-β1. Data
presented here indicate that gene modification can specifically be
targeted to keratinocytes through the K14 promoter or nonspecifically
through a retroviral promoter, each of which has potential advantages
and disadvantages. As we have demonstrated in this study, the K14
promoter specifically drives the expression of the gene of interest, such
as TGF-β1, in both primary and CL-177 keratinocyte cells but not in
mesenchymal cells. The K14 promoter was chosen for this study
because it has successfully been used in a transgenic model and its
activity in stratified squamous epithelial cells has been reported (Vassar
et al, 1989). It has also been used successfully to drive the expression
of IL-6 cDNA in the skin of transgenic mice (Turksen et al, 1992).
Although the K14 promoter directs the expression of TGF-β1 to
keratinocytes in a specific way, using this promoter in a plasmid vector
with low transfection efficiency and low stability might be considered
disadvantageous. Retroviral mediated gene transfer leads to stable
integration of the gene of interest into the genome of keratinocytes.
Eming et al (1996) recently used this approach to introduce the human
IGF-1 gene with a rate of gene transduction greater than 50% in
primary cultured keratinocytes. Genetically modified keratinocytes
then showed a significant increase in the secretion of IGF-1 both
in vivo and in vitro relative to untransduced cells. Another potential
advantage of this technique is that transduced cells can be selected by
culture in the presence of antibiotic. In contrast to the previous
approach, retroviral mediated gene transfer lacks specificity and virus
can enter all cells carrying viral receptors. This may be an obstacle
when in vivo transduction is required but this lack of specificity may
not be an important issue when delivering a gene product to the
wound site through sheets of cultured keratinocytes. This is because
the viral vectors used in our study were genetically modified to make
them replication incompetent. Development of fibrotic condition due
to overexpression of TGF-β1 from sheets of either K14-TGF-β1 or
pLin-TGF-β1 transduced keratinocytes is also unlikely to be a problem
in our system for two reasons. First, the genetically modified ker-
atinocyte sheet used as a wound coverage is temporary and is dislodged
following natural epithelialization, and second, TGF-β1 is released in
a latent form and becomes activated when activation factors such as
proteases are present in the wound environment. As in a normal
condition, the mechanism of TGF-β1 activation may not be functional
following epithelialization.
TGF-β1 released from pLin-TGF-β1 transduced keratinocytes
grown in the upper chamber of a coculture system was able to stimulate
synthesis of collagen by dermal fibroblasts (Fig 5B), even though it
was found to be inactive in the traditionally used mink lung epithelial
cell growth inhibition assay (data not shown). We have recently
reported that treatment of dermal fibroblasts with IGF-1 induces
production of latent TGF-β1 and that this effect is probably mediated
at least in part by auto-induction of TGF-β1 because it can be blocked
by TGF-β1 neutralizing antibody (Ghahary et al, 1998). Both these
observations suggest that dermal fibroblasts may have a mechanism to
activate the latent TGF-β1.
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In summary, data presented here clearly demonstrate that primary
cultured keratinocytes can be genetically modified to express high
levels of a multifunctional growth factor such as TGF-β1. This approach
has potential for the development of novel therapies for the treatment
of a broad range of dermal diseases.
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